Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 30;10(7):1390.
doi: 10.3390/jcm10071390.

Biologics for Psoriasis during the COVID-19 Pandemic

Koji Kamiya  1 , Mayumi Komine  1 , Mamitaro Ohtsuki  1
Affiliations
Review

Biologics for Psoriasis during the COVID-19 Pandemic

Koji Kamiya et al. J Clin Med. .

Abstract

Psoriasis is a chronic, immune-mediated inflammatory disease that predominantly affects the skin and joints. The recent therapeutic development for psoriasis has been remarkable and biologics have dramatically changed the treatment of psoriasis. In moderate-to-severe cases, systemic therapies are required to control their symptoms and biologics can provide greater efficacy when compared with other types of therapies. The coronavirus disease (COVID-19) pandemic has had a great impact on the lives of many people and has worsened substantially worldwide. During the ongoing COVID-19 pandemic, it still remains unclear whether biologics suppress the immune system and increase the risk of COVID-19. In this review, we have summarized the experience with biologics used for treating psoriasis during the COVID-19 pandemic. Biologics seem to be beneficial to COVID-19 infection. Shared decision-making that is based on updated information is highlighted in the time of COVID-19.

Keywords: COVID-19; SARS-CoV-2; biologics; psoriasis; systemic therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Biologics for psoriasis and COVID-19. Tumor necrosis factor (TNF) inhibitors and interleukin (IL)-17 inhibitors have the potential to prevent the infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the cytokine storm of COVID-19.
See this image and copyright information in PMC

References

    1. Nestle F.O., Kaplan D.H., Barker J. Psoriasis. N. Engl. J. Med. 2009;361:496–509. doi: 10.1056/NEJMra0804595. - DOI - PubMed
    1. Boehncke W.H., Schon M.P. Psoriasis. Lancet. 2015;386:983–994. doi: 10.1016/S0140-6736(14)61909-7. - DOI - PubMed
    1. Honma M., Hayashi K. Psoriasis: Recent progress in molecular-targeted therapies. J. Dermatol. 2021 doi: 10.1111/1346-8138.15727. - DOI - PubMed
    1. Caiazzo G., Fabbrocini G., Di Caprio R., Raimondo A., Scala E., Balato N., Balato A. Psoriasis, cardiovascular events, and biologics: Lights and shadows. Front. Immunol. 2018;9:1668. doi: 10.3389/fimmu.2018.01668. - DOI - PMC - PubMed
    1. Sajja A.P., Joshi A.A., Teague H.L., Dey A.K., Mehta N.N. Potential immunological links between psoriasis and cardiovascular disease. Front. Immunol. 2018;9:1234. doi: 10.3389/fimmu.2018.01234. - DOI - PMC - PubMed

LinkOut - more resources